BICO - The Bio Convergence Company WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: KeXStarQ
Darüber diskutieren die Nutzer
Die User diskutieren über die aktuelle Situation von BICO Group AB. Ein User namens Teamplayer ist der Meinung, dass das Unternehmen zu viele Verluste macht und der Aktienkurs auf 2,50€ fallen wird, wenn die Quartalszahlen veröffentlicht werden. PaulR90 ist gespannt auf den 22. August. Ein anderer User namens Jumbopeitsche erklärt, dass der freie Cashflow des Unternehmens weiter schrumpft und der Umsatz voraussichtlich unter den Erwartungen liegen wird.
BICO Group AB (publ) announces that Erik Gatenholm, after initiating discussions with the Board of Directors, has decided to step down as President and CEO of BICO Group. Maria Forss has been appointed new President and CEO. Maria Forss will assume office on November 27, 2023, or sooner. Maria Forss has been appointed new President and CEO and will assume office on November 27, 2023, or sooner. Maria Forss (born 1972) has extensive international experience from leading positions in both medtech and pharma companies, such as Vitrolife and AstraZeneca. The last years within Vitrolife Maria Forss has as the Senior Vice President led the Consumables Business Area and before that she was the Vice President of Business Development and Global Marketing. Maria Forss has successfully developed businesses through the whole value chain and in the whole product life cycle as well as acquisitions and integration of companies. The Board of Directors has, together with Erik Gatenholm, concluded that the timing is right for a new CEO and President. This discussion was initiated by Erik Gatenholm, and he has together with the board concluded that in the next phase BICO needs a CEO with strong operating skills and experience in scaling a global organization. “On behalf of the Board of Directors, I would like to welcome Maria Forss. She has profound leadership skills and life science experience, which will secure steadfast focus during BICO’s further development and create shareholder value”, says Rolf Classon, Chairman of the Board, BICO Group AB. “I would also like to thank Erik Gatenholm for his vision and dedication to build a strong life science company. During his tenure the company has evolved into a Group which is built on a market leading commercial portfolio.” In order to enable a seamless transition, Erik Gatenholm will remain in his current position until Maria Forss assumes as new President and CEO. To secure continuity Erik Gatenholm will, as major shareholder, also remain in his role as board member of BICO. ..
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | Novavax Hauptdiskussion | +7,22 % | |
| 2 | BAYER Hauptdiskussion | -2,87 % | |
| 3 | Outlook Therapeutics Hauptdiskussion | +5,61 % | |
| 4 | Trading- und Aktien-Chat | ||
| 5 | MEYER BURGER Hauptdiskussion | -15,37 % | |
| 6 | Dax Prognose | -0,83 % | |
| 7 | BED BATH & BEYOND Hauptdiskussion | -28,27 % | |
| 8 | GIGASET AG Hauptdiskussion | -1,35 % | |
| 9 | für alle, die es ehrlich meinen beim Traden. | ||
| 10 | SQUARE INC. A Hauptdiskussion | -2,93 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | Novavax Hauptdiskussion | +7,56 % | |
| 2 | BAYER Hauptdiskussion | -2,87 % | |
| 3 | Outlook Therapeutics Hauptdiskussion | +5,61 % | |
| 4 | MEYER BURGER Hauptdiskussion | -15,37 % | |
| 5 | GIGASET AG Hauptdiskussion | -1,35 % | |
| 6 | SQUARE INC. A Hauptdiskussion | -2,94 % | |
| 7 | BED BATH & BEYOND Hauptdiskussion | -28,27 % | |
| 8 | Nio für normale Kommunikation | -1,43 % | |
| 9 | PAYPAL Hauptdiskussion | -1,73 % | |
| 10 | T2 Biosystems | -6,82 % | Alle Diskussionen |